About
Velicept developed solabegron, a selective beta-3 adrenergic receptor agonist aimed at treating overactive bladder (OAB) and irritable bowel syndrome (IBS). The company ceased operations in 2020.
Explore Velicept's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.